Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Partial-Blind, Placebo-controlled, Sequential Dose Group, Ascending, Multiple Dose Study of the Safety, Tolerability and Pharmacokinetics, With Food Effect, of CMX157 in Healthy Subjects

Next Previous
Trial Profile

A Phase 1, Randomized, Partial-Blind, Placebo-controlled, Sequential Dose Group, Ascending, Multiple Dose Study of the Safety, Tolerability and Pharmacokinetics, With Food Effect, of CMX157 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenofovir exalidex (Primary)
  • Indications Hepatitis B; Infections
  • Focus Adverse reactions
  • Sponsors ContraVir Pharmaceuticals; Hepion Pharmaceuticals

Most Recent Events

  • 20 Apr 2017 According to a ContraVir Pharmaceuticals media release, results from this trial were presented at The International Liver Congress (ILC) 2017, the annual meeting of the European Association for the Study of the Liver (EASL).
  • 18 Mar 2017 Results (n=10) presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
  • 05 Dec 2016 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top